NAPP LABORATORIES LIMITED
Get an alert when NAPP LABORATORIES LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-06-12 (in 1mo)
Last made up 2025-05-29
Watchouts
None on the register
Cash
£37K
0% vs 2023
Net assets
£14M
+2% vs 2023
Employees
—
Average over period
Profit before tax
£365K
+8% vs 2023
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £13,272,000 | £13,916,000 | |
| Operating profit | £327,000 | £364,000 | |
| Profit before tax | £338,000 | £365,000 | |
| Net profit | £231,000 | £274,000 | |
| Cash | £37,000 | £37,000 | |
| Total assets less current liabilities | £13,979,000 | £14,259,000 | |
| Net assets | £13,979,000 | £14,259,000 | |
| Equity | £13,979,000 | £14,259,000 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 2.5% | 2.6% | |
| Net margin | 1.7% | 2.0% | |
| Return on capital employed | 2.3% | 2.6% | |
| Current ratio | 9.80x | 5.67x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company's business activities, together with the factors likely to affect its future development are described in the Strategic Report. Napp Laboratories Limited is a member of the Napp Pharmaceutical Holdings Limited group, and is subject to the overall financing arrangements of the group. As such the Company has received a formal letter of support from the Company's parent undertaking, Napp Pharmaceutical Holdings Limited, guaranteeing continued financial support to enable the Company to meet its liabilities to creditors as they fall due for the period to 31 August 2026. The directors have assessed that Napp Pharmaceutical Holdings Limited has sufficient resources to provide such support notwithstanding the risks and uncertainties disclosed in its consolidated financial statements. The Company expects to see continued demand for its product portfolio, which notably contains many well-established products treating chronic conditions. The groups' latest financial projections show that the group remains in a strong position to support the Company through to 31 August 2026. Based on this assessment the directors continue to adopt the going concern basis in preparing the annual report and accounts.”
Significant events
- “On 02 July 2025, the Board of the Company declared an interim dividend distribution of $3,291 equivalent to £2,409.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JAMIESON, Stephen Johan | Director | 2019-02-22 | Sep 1957 | British |
| LEA, Bryan George | Director | 1999-01-29 | Jun 1961 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CORNHILL SERVICES LIMITED | Corporate Secretary | 2008-03-25 | 2009-02-26 |
| TIERCEL SERVICES LIMITED | Corporate Secretary | 2009-02-26 | 2018-06-11 |
| TIERCEL SERVICES LIMITED | Corporate Secretary | — | 2008-03-25 |
| BAKER, Stuart David | Director | 2017-08-08 | 2019-12-31 |
| BASHFORTH, Simon John | Director | 1994-01-24 | 2012-04-06 |
| BROGDEN, John Robert | Director | — | 2005-03-30 |
| CHAPLIN, John Richard | Director | — | 1999-09-09 |
| HEALEY, Michael John | Director | 1995-05-04 | 2005-03-30 |
| LESLIE, Stewart T | Director | — | 1997-12-31 |
| LYNCH, Michael Howard | Director | 1999-01-29 | 2012-12-31 |
| MANNERS, Paul | Director | — | 2001-12-31 |
| MATTESSICH, Antony Charles | Director | 2005-04-01 | 2017-07-31 |
| MILLER, Allan John | Director | — | 2003-05-29 |
| MITCHELL, Christopher Benbow | Director | — | 2018-04-12 |
| WIKSTROM, Ake Gunnar | Director | 2018-04-12 | 2019-02-22 |
| WIKSTROM, Ake Gunnar | Director | 2001-09-05 | 2011-05-19 |
| WILLIAMSON, Kenneth Lawrie, Dr | Director | 2002-06-28 | 2009-03-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Napp Pharmaceutical Group Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 163 total filings
Material constitutional events — rename, articles re-file, resolution
- 2020-10-06 RESOLUTIONS Resolution
- 2020-10-06 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-11-17 | CH01 | officers | Change person director company with change date | |
| 2025-09-09 | AA | accounts | Accounts with accounts type full | |
| 2025-05-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-02-06 | AD02 | address | Change sail address company with old address new address | |
| 2025-02-05 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-12-12 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-08-27 | AA | accounts | Accounts with accounts type full | |
| 2024-06-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-04 | CH01 | officers | Change person director company with change date | |
| 2023-10-14 | AA | accounts | Accounts with accounts type full | |
| 2023-06-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-14 | AA | accounts | Accounts with accounts type full | |
| 2022-07-04 | CH01 | officers | Change person director company with change date | |
| 2022-06-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-01 | AA | accounts | Accounts with accounts type full | |
| 2021-07-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-01-08 | AA | accounts | Accounts with accounts type full | |
| 2020-10-06 | RESOLUTIONS | resolution | Resolution | |
| 2020-10-06 | MA | incorporation | Memorandum articles | |
| 2020-06-08 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+4.9%
£13,272,000 £13,916,000
-
Cash
0%
£37,000 £37,000
-
Net assets
+2%
£13,979,000 £14,259,000
-
Employees
—
Not reported
-
Operating profit
+11.3%
£327,000 £364,000
-
Profit before tax
+8%
£338,000 £365,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers